Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that data from its MCLA-128 and MCLA-129 programs will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts. Presentation and Poster Details: MCLA-128 Presentation Title: Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancersAuthors: Alison M Schram, Eileen M O'Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, David Maussang, Ernesto Wasserman, Marc Ladanyi, David M Hyman, L Andres Sirulnik, Alexander E DrilonSession: Spotlight on Proffered Papers 1Location: Level 3 - Ballroom ABDate and Time: Su
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus (NASDAQ: MRUS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $73.00 price target on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.MarketBeat
- Merus to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Merus to Present at Upcoming Investor ConferencesGlobeNewswire
- Merus Receives FDA extension of PDUFA for zenocutuzumabGlobeNewswire
MRUS
Earnings
- 8/1/24 - Miss
MRUS
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- MRUS's page on the SEC website